Company Encyclopedia
View More
name
Scynexis
SCYX.US
SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company’s lead product candidate is Ibrexafungerp, a drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases.
4.513 T
SCYX.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
PharmaceuticalsIndustry
Industry Ranking152/183
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-53.29%E
    • Profit Margin-862.89%E
    • Gross Margin100.00%A
  • Growth ScoreE
    • Revenue YoY-65.77%E
    • Net Profit YoY30.57%B
    • Total Assets YoY-48.43%E
    • Net Assets YoY-37.76%E
  • Cash ScoreE
    • Cash Flow Margin-11.59%D
    • OCF YoY-65.77%E
  • Operating ScoreE
    • Turnover0.04E
  • Debt ScoreB
    • Gearing Ratio28.67%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Scynexis completes transfer of Brexafemme New Drug Application To GSK

    Nov 19 (Reuters) - SCYNEXIS Inc:* SCYNEXIS COMPLETES TRANSFER OF BREXAFEMME® NEW DRUG APPLICATION TO GSK* SCYNEXIS INC - TO RECEIVE UP TO $145.5 MILLION IN ANNUAL NET SALES MILESTONES AS WELL AS ROYALTIES Source text: Further company coverage:

    Reuters·
    US
    GSK
    -0.93%
    US
    SCYX
    -2.09%
    UK
    GSK
    0.00%
    Reuters·
    US
    GSK
    -0.93%
    US
    SCYX
    -2.09%
    UK
    GSK
    0.00%

    Scynexis Announces Federal Funding of Collaboration Between Hackensack Meridian CDI and Johns Hopkins Researchers to Develop New Therapeutics, Including Novel Fungerps, for Resistant Fungal Infections

    JERSEY CITY, N.J., Nov. 17, 2025 ( GLOBE NEWSWIRE ) -- SCYNEXIS, Inc. ( NASDAQ: SCYX ) , a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that a novel series of antifungal compounds utilizing ...

    GlobeNewswire·
    US
    SCYX
    -2.09%
    GlobeNewswire·
    US
    SCYX
    -2.09%

    SCYNEXIS and Partners Secure $7 Million Annual NIH Grant for Novel Antifungal Development

    SCYNEXIS Inc. and partners have secured a $7 million annual grant from the NIH to develop novel antifungal compounds. The five-year grant supports a consortium led by Hackensack Meridian CDI and Johns Hopkins Bloomberg School of Public Health. The funding will aid the Center of Excellence in Translational Research in advancing therapeutics for resistant fungal infections, including SCYNEXIS's next-generation fungerp candidates.

    Reuters·
    US
    SCYX
    -2.09%
    Reuters·
    US
    SCYX
    -2.09%

    Guggenheim Reaffirms Their Buy Rating on SCYNEXIS (SCYX)

    Guggenheim has reaffirmed a Buy rating on SCYNEXIS (SCYX) with a price target of $3.00. Additionally, Maxim Group's Jason McCarthy also issued a Buy rating on the same stock. However, TR | OpenAI maintained a Hold rating on SCYNEXIS on the same day.

    Tip Ranks·
    US
    SCYX
    -2.09%
    Tip Ranks·
    US
    SCYX
    -2.09%

    SCYNEXIS Reports Q3 2025 Financial Results and Strategic Updates

    SCYNEXIS Inc (SCYX) reported its Q3 2025 financial results, revealing a net loss of $8.6 million, up from $2.8 million in Q3 2024. The company, focused on antifungal medicines, highlighted its lead product ibrexafungerp and its partnership with GlaxoSmithKline (GSK). Revenue from license agreements decreased, while high operating expenses continued due to R&D efforts. SCYNEXIS aims to advance its second-generation antifungal, SCY-247, through clinical trials and remains optimistic about future growth in the antifungal market.

    Tip Ranks·
    US
    SCYX
    -2.09%
    Tip Ranks·
    US
    SCYX
    -2.09%
    © 2025 Longbridge｜Disclaimer